10-Q: Iris Acquisition Corp Reports Net Loss of $858,231 in First Quarter 2024 Amidst Business Combination Efforts

Iris Acquisition Corp reported a net loss of $858,231 for the quarter ended March 31, 2024, as it continues to pursue a business combination with Liminatus Pharma.

Summary

• Iris Acquisition Corp, a blank check company, reported a net loss of $858,231 for the three months ended March 31, 2024.
• The company's operating costs were $721,754, and it experienced an unrealized loss on warrant liabilities of $178,734.
• Interest income from the trust account partially offset these losses, amounting to $47,241.
• The company's cash balance was $201,537, which includes $76,639 of restricted cash for tax payments.
• The company has a working capital deficit of approximately $5,438,233.
• The company is pursuing a business combination with Liminatus Pharma, with a deadline extended to September 9, 2024.
• There is substantial doubt about the company's ability to continue as a going concern if a business combination is not completed by the deadline.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the significant net loss, working capital deficit, going concern warning, and the need for a deadline extension. The company is facing significant challenges in completing its business combination and has material weaknesses in internal controls.

Positives

• The company has $3,118,739 in a trust account which can be used for a business combination.
• The company is actively pursuing a business combination with Liminatus Pharma.

Negatives

• The company reported a significant net loss of $858,231 for the quarter.
• The company has a substantial working capital deficit of approximately $5,438,233.
• There is substantial doubt about the company's ability to continue as a going concern if a business combination is not completed by September 9, 2024.
• The company experienced an unrealized loss of $178,734 on the change in fair value of warrant liabilities.
• The company's operating costs were $721,754 for the quarter.

Risks

• The company may not be able to complete a business combination by the deadline of September 9, 2024.
• The company may need to obtain additional financing to complete the business combination or to meet obligations after the combination.
• The company's working capital deficit raises concerns about its ability to continue as a going concern.
• The company's financial statements are subject to material weaknesses in internal controls.
• The company is subject to a 1% excise tax on share repurchases, which could reduce the value of the Class A common stock or cash available for a business combination.
• The company's warrants are subject to fair value fluctuations, which can impact the company's financial results.

Future Outlook

The company is focused on completing its business combination with Liminatus Pharma by September 9, 2024, but there is substantial doubt about its ability to continue as a going concern if the combination is not completed by this date.

Management Comments

• Management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company's ability to continue as a going concern.
• Management has determined that if the Company is unable to complete a Business Combination by September 9, 2024, then the Company will cease all operations except for the purpose of liquidating.

Industry Context

This announcement is typical for a special purpose acquisition company (SPAC) that is nearing its deadline to complete a business combination. The financial results reflect the lack of operating revenue and the costs associated with maintaining the company and pursuing a transaction. The extension of the deadline and the going concern warning are common in SPACs that have not yet completed a deal.

Comparison to Industry Standards

• The financial performance of Iris Acquisition Corp is consistent with other pre-merger SPACs, which typically report losses due to operating expenses and fair value adjustments of warrants.
• The level of cash in the trust account is typical for a SPAC of this size, but the working capital deficit is a concern.
• The extension of the business combination deadline is a common occurrence in the SPAC market, as many SPACs struggle to find suitable targets within the initial timeframe.
• The going concern warning is also not uncommon for SPACs that are nearing their liquidation deadline without a completed merger.
• Comparable companies include other SPACs that have extended their deadlines and are facing similar challenges in completing a business combination, such as those listed on the Nasdaq Capital Market.

Related Party Transactions

• The company has related party loans with its sponsor, Iris Acquisition Holdings LLC.
• The company entered into an administrative support agreement with Arrow Capital Management LLC, a related party.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company fails to complete a business combination by the deadline.
• Employees may be impacted by the uncertainty surrounding the company's future.
• Creditors may be at risk if the company is unable to meet its obligations.
• The company's potential liquidation could impact all stakeholders.

Next Steps

• The company must complete its business combination with Liminatus Pharma by September 9, 2024.
• The company needs to address the material weaknesses in its internal controls.
• The company may need to secure additional financing to complete the business combination.
• The company must demonstrate compliance with all applicable requirements for initial listing on the Nasdaq Global Market by September 3, 2024.

Key Dates

Keywords

Business Combination, SPAC, Liminatus Pharma, Net Loss, Warrant Liabilities, Working Capital, Going Concern, Trust Account, Redemption, Excise Tax